Literature DB >> 15380938

Targeting the tumor vascular compartment to improve conventional cancer therapy.

Olivier Feron1.   

Abstract

The fact that a single blood vessel can support the life of thousands of tumor cells has been known for a long time. However, therapeutic strategies that aim to impair vascular development in tumors are only slowly emerging in the clinics. Nevertheless, the accumulation of data from many successful preclinical studies of the effects of a variety of drugs that target tumor vasculature provides clues that should help rationalize future treatment modalities for human tumors. Indeed, the 'old' view of an immature and non-functional vascular network within tumors has evolved and, in this article, we will show that the concept of tumor heterogeneity should be extended to the vascular compartment. In addition, we will review recent data documenting that both mature and immature vessels coexist within tumors and, importantly, that their relative density responds to a dynamic process that evolves with time and treatments.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15380938     DOI: 10.1016/j.tips.2004.08.008

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  11 in total

Review 1.  Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?

Authors:  Iris Helfrich; Dirk Schadendorf
Journal:  Mol Oncol       Date:  2011-02-03       Impact factor: 6.603

Review 2.  Tackling TAMs for Cancer Immunotherapy: It's Nano Time.

Authors:  Yishun Yang; Jianfeng Guo; Leaf Huang
Journal:  Trends Pharmacol Sci       Date:  2020-10       Impact factor: 14.819

Review 3.  Nanovehicular intracellular delivery systems.

Authors:  Ales Prokop; Jeffrey M Davidson
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

Review 4.  Magnetic resonance elastography (MRE) in cancer: Technique, analysis, and applications.

Authors:  Kay M Pepin; Richard L Ehman; Kiaran P McGee
Journal:  Prog Nucl Magn Reson Spectrosc       Date:  2015-06-23       Impact factor: 9.795

5.  Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model.

Authors:  Boris Gorelik; Irit Ziv; Revital Shohat; Michael Wick; W David Hankins; David Sidransky; Zvia Agur
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

6.  MT-MMPS as Regulators of Vessel Stability Associated with Angiogenesis.

Authors:  Nor Eddine Sounni; Alexandra Paye; Lorin Host; Agnès Noël
Journal:  Front Pharmacol       Date:  2011-05-13       Impact factor: 5.810

7.  Targeting tumor perfusion and oxygenation to improve the outcome of anticancer therapy.

Authors:  Bénédicte F Jordan; Pierre Sonveaux
Journal:  Front Pharmacol       Date:  2012-05-21       Impact factor: 5.810

8.  Microbubble and ultrasound radioenhancement of bladder cancer.

Authors:  W T Tran; S Iradji; E Sofroni; A Giles; D Eddy; G J Czarnota
Journal:  Br J Cancer       Date:  2012-07-12       Impact factor: 7.640

9.  High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile.

Authors:  M M Baldewijns; V L Thijssen; G G Van den Eynden; S J Van Laere; A M Bluekens; T Roskams; H van Poppel; A P De Bruïne; A W Griffioen; P B Vermeulen
Journal:  Br J Cancer       Date:  2007-05-15       Impact factor: 7.640

10.  Tumor-penetrating peptides.

Authors:  Tambet Teesalu; Kazuki N Sugahara; Erkki Ruoslahti
Journal:  Front Oncol       Date:  2013-08-27       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.